Table of Contents Author Guidelines Submit a Manuscript
Journal of Automatic Chemistry
Volume 20 (1998), Issue 4, Pages 111-115

Laboratory automation —some perspectives on the challenges in the implementation of the technology in pharmaceutical development

1Pharmaceutical Technologies, SmithKline Beecham Pharmaceuticals, Essex, Harlow, UK
2Analytical Development, SmithKline Beecham Pharmaceuticals, Sussex, Crawley, UK

Copyright © 1998 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The intensifying pressure on reducing the development time for new pharmaceutical products is resulting in an increasing need for laboratory automation. A key element for the successful implementation of robotics for drug product analysis is the establishment of a reliable process for interaction of the automation team with its various customers, for example development product team and manufacturing group. The reduction of cycle time for product development appears to be resulting in more stability studies to support NDA/MAA filings for several reasons. Key clinical information may not be available before initiation of the stability studies and simultaneous world-wide development may result in an increase in the number of product strength and pack options.